Callum McKenzie

Callum McKenzie, Ph.D., is a Principal Scientist at Epsilogen Ltd, focusing on the development of IgE antibodies for immuno-oncology applications. Prior to this role, Callum held multiple positions at Autolus Ltd, where responsibilities included leading the synthetic immuno-biology group and developing novel chimeric antigen receptor (CAR) T cell therapies for cancer treatment. Callum also contributed to the R&D Immuno-Oncology team at Cell Medica, generating CAR-NKT and TCR-engineered therapies, and conducted post-doctoral research at the MRC Laboratory of Molecular Biology, investigating molecular mechanisms in cancers. Academic credentials include a Ph.D. in Molecular and Cell Biology from the University of Cambridge and a Master’s degree from the University of Bath.